Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.

Salma YounesEleonora NicolaiMassimo PieriSergio BernardiniHanin I DaasDuaa W Al-SadeqNadin YounesFarah M ShurrabParveen B NizamuddinFathima HumairaNader Al-DewikHadi M YassineLaith Jamal Abu-RaddadAhmed IsmailGheyath K Nasrallah

Published in: Influenza and other respiratory viruses (2024)

The results emphasize the potential benefit of using heterologous mRNA boosters to increase antibody levels and neutralizing capacity particularly in patients who received primary vaccination with ChAdOx1.

Keyphrases

sars cov
dengue virus
saccharomyces cerevisiae
binding protein
respiratory syndrome coronavirus
zika virus
aedes aegypti